Rapport Therapeutics, Inc. (RAPP) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US75383L1026
Rapport Therapeutics, Inc. financials
| Fiscal year | 2025 |
|---|---|
| Operating income | -125.10 m USD |
| EBIT | -125.10 m USD |
| Net income | -111.48 m USD |
| Diluted EPS – continuing operations | -2.86 USD |
Full history since 2022, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Rapport Therapeutics, Inc.
Rapport Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company that focuses on the discovery and development of transformational small molecule medicines for patients suffering from central nervous system (CNS) disorders. The company's lead product candidate is receptor associated protein (RAP)-219, an investigational small molecule that is designed to inhibit TARPy8-containing AMPARs with picomolar affinity for the treatment of focal epilepsy and other CNS disorders, including peripheral neuropathic pain and bipolar disorder. It also develops nicotinic acetylcholine receptor (nAChR) programs, such as a6 nAChR to treat chronic pain and migraine; and a9a10 nAChR for the treatment of hearing/vestibular disorders. The company was formerly known as Precision Neuroscience NewCo, Inc. and changed its name to Rapport Therapeutics, Inc. in October 2022. Rapport Therapeutics, Inc. was incorporated in 2022 and is headquartered in Boston, Massachusetts.
More stocks
- ECOPRO MAT (450080.KS)
- Burke & Herbert Financial Services Corp. (BHRB)
- BH Macro Limited (BHMU.L)
- ChronoScale Holdings Corp (CHRN)
- Bilia AB (BILI A.ST)
- Hubei TKD Crystal Electn (603738.SS)
- Shanxi Zhangze Electric Power Co Ltd (000767.SZ)
- Supermarket Income REIT PLC (SUPR.L)
- Jiangsu Shuangxing Color Plastic New Materials Co Ltd (002585.SZ)
- FLEX LNG Ltd (FLNG)
- Cembre SpA (CMB.MI)
- Yangling Metron New Material Co Ltd (300861.SZ)
Not investment advice. All data without warranty, price as of 04.11.2026. Details in the risk notice.